NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a Healthcare company (Biotechnology) with a market capitalization of $107M. The Maz Rating grades it against the other companies in its sector.
NRx Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.45, NRx Pharmaceuticals, Inc. trades at 24.0x sales. Over the last twelve months it generated about $4M of revenue and a net loss of $24M. It runs a gross margin of 25.2%, an operating margin of -556.5% and a net margin of -458.5%. It shows return on equity of 247.8%, return on invested capital of 2380.2% and a free cash flow yield of -22.9%. On the balance sheet: a debt-to-equity ratio of -0.49 and a current ratio of 0.76. Over the past 52 weeks the share price ranged from $1.62 to $5.06, with a beta of 2.07.
NRx Pharmaceuticals, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, NRx Pharmaceuticals, Inc. (NRXP) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.88% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.1% / 30% · Interest income / Revenue 0.35% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.88% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.8% / 33% · Receivables / Mkt Cap (36m) 0.20% / 49% · Interest income / Revenue 0.35% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.88% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.8% / 33.33% · Receivables / Mkt Cap (24m) 0.20% / 33.33% · Interest income / Revenue 0.35% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 2.40% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 70.3% / 33.33% · Receivables / Avg Assets (4Q) 0.88% / 33.33% · Interest income / Revenue 0.35% / 5% | Fail |
| FTSE | Debt / Total Assets 3.52% / 33.33% · (Cash+ST Inv) / Total Assets 71.3% / 33.33% · (Cash+Recv) / Total Assets 72.0% / 33.33% · Interest income / Revenue 0.35% / 5% | Fail |
It depends on the standard you follow. As of September 2026, NRx Pharmaceuticals, Inc. (NRXP) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. NRx Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.35% of each dividend: NRx Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.